The difference between dasatinib and imatinib

Dasatinib and imatinib are both drugs used to treat chronic myeloid leukemia (CML). They have some differences in pharmacology, pharmacodynamics and side effects.

1. Pharmacological mechanism:

Imatinib is a tyrosine kinase inhibitor that prevents the proliferation of cancer cells by inhibiting the activity ofBCR-ABL fusion protein. In addition, imatinib can also inhibit other related tyrosine kinases such as c-Kit and PDGFR. Dasatinib is also a tyrosine kinase inhibitor and can inhibit a wider range of tyrosine kinases than imatinib. In addition to BCR-ABL, it can also inhibit Src family kinases, Eph family kinases, etc. Therefore, dasatinib has broader antitumor activity.

2. Pharmacodynamic performance:

Imatinib is the drug of choice for the treatment of chronic myeloid leukemia and has been widely used in clinical practice. Most patients respond well to imatinib, achieving durable complete or partial responses. However, some patients may develop resistance to imatinib during treatment. At this time, dasatinib becomes an important choice. Compared with imatinib, dasatinib has stronger anti-tumor activity in imatinib-resistant patients, and its in vitro potency against engineered cell lines expressing non-mutated BCR-ABL is 325 times that of imatinib.

3. Drug metabolism and side effects:

Imatinib and dasatinib are both metabolized in the liver by the enzyme CYP3A4. However, dasatinib is metabolized rapidly and has a short elimination half-life. This means dasatinib requires more frequent dosing to maintain effective drug concentrations. Both drugs may cause some common adverse reactions, such as nausea, vomiting, diarrhea, bone marrow suppression, etc. However, due to differences in its pharmacology, dasatinib may also cause additional side effects, such as fluid retention, cardiovascular problems, immune dysfunction, etc. Therefore, patients' cardiac function and fluid balance require close monitoring while using dasatinib.

4. Clinical studies: In the CA180-034 trial for patients with imatinib-resistant or imatinib-intolerant chronic myelogenous leukemia, dasatinib 100 mg once daily (QD) showed durable efficacy and safety, including a 5-year progression-free survival rate (PFS) of 57%, an overall survival rate (OS) of 78%, and a 5-year cumulative major molecular response rate (MMR) of 44%. The approval of dasatinib in the first-line CML-CP setting provides an important treatment option compared to imatinib, allowing patients to achieve faster and deeper treatment responses.

To summarize, dasatinib and imatinib are two commonly used drugs for the treatment of chronic myeloid leukemia. Although they have some differences in pharmacology, pharmacodynamics and side effects, they are all widely used in clinical practice. When selecting drugs, doctors will consider the patient's specific situation, drug resistance, and risk of adverse reactions, and make decisions based on an individualized treatment plan.